32. Gastric neuroendocrine carcinoma and gastric carcinoma with neuroendocrine cell differentiation: A clinical and prognostic analysis
Original Article

32. Gastric neuroendocrine carcinoma and gastric carcinoma with neuroendocrine cell differentiation: A clinical and prognostic analysis

Hui-Fang Wang1, Ai-Wen Wu2, Peng Yuan3, Yi-Qiang Liu4, Jia-Fu Ji2

1Department of General Surgery, The First Hospital of Ningbo, Ningbo 315010, China; 2Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Gastrointestinal Surgery, Peking University Cancer Hospital, Beijing Cancer Hospital and Institute, Beijing 100142, China; 3Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital, Beijing Cancer Hospital and Institute, Beijing 100142, China; 4Department of pathology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital, Beijing Cancer Hospital and Institute, Beijing 100142, China

Objective: To investigate the clinical and pathological features as well as treatment and prognosis of gastric neuroendocrine carcinoma and gastric carcinoma with neuroendocrine cell differentiation, and to improve the level of its diagnosis and treatment.
Methods: Retrospectively analysis 19 cases of gastric cancer and gastric neuroendocrine neuroendocrine differentiation in Beijing Cancer Hospital from January 1997 to December 2008, according to the International Classification of Disease for Oncology (2000). The 19 cases were divided into gastric carcinoid type I, III type sporadic gastric carcinoid, small cell carcinoma of the stomach, and gastric cancer with neuroendocrine cell differentiation. Comparing the subgroups into age, location, clinic performance, pathology and the interaction between pathological type, diameter, muscle layer invasion, liver metastasis and survival.
Results: Two cases gastric carcinoid type I(10.5%), 9 cases III type sporadic gastric carcinoid (47.4%), 3 cases small cell carcinoma of the stomach (15.8%), and 5 cases gastric cancer with neuroendocrine cell differentiation were identified. Gastric neuroendocrine carcinoma are likely located in the fundus and body of the stomach. Esophagus were invaded by gastric neuroendocrine carcinoma in five cases (35.7%). Gastric carcinoma with neuroendocrine cell differentiation can derive from any location of the stomach. There’s no significant affection on survival with pathological type, tumor diameter, lymphvascular invasion (P>0.05). There are significant affection on survival with the muscle layer invasion and liver metastasis (P<0.05).
Conclusions: Gastric neuroendocrine carcinoma are likely located in the fundus and body of the stomach, gastric carcinoma with neuroendocrine cell differentiation can derive from any location of the stomach. There are significant association with survival in muscle layer invasion and liver metastasis.

Key words

Stomach; gastric neuroendocrine carcinoma; gastric carcinoma with neuroendocrine differentiation; prognosis

DOI: 10.3978/j.issn.2224-4778.2012.s032